

S/N 09/689,136

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John F. Engelhardt et al. Examiner: Daniel M Sullivan
Serial No.: 09/689,136 Group Art Unit: 1636
Filed: October 12, 2000 Docket: 875.032US1
Title: COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants hereby authorize the Commissioner to charge the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 19-0743.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

JOHN F. ENGELHARDT ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date

May 19, 2005

By

Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 18 day of May, 2005.

Name

CANDIS BUENDING


Signature



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/689,136
Filing Date	October 12, 2000
First Named Inventor	Engelhardt, John
Group Art Unit	1636
Examiner Name	Sullivan, Daniel

Sheet 1 of 1

Attorney Docket No: 875.032US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2005/0037497 A1	02/17/2005	Engelhardt, J. F., et al.	03/31/2004
	US-2005/0095225 A1	05/05/2005	Engelhardt, J. F., et al.	03/31/2004
	US-6,897,045	05/24/2005	Engelhardt, J. F., et al.	01/22/2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	CA-2302627	09/23/2001	Yves, B. , et al.	
	WO-98/53839A2	12/03/1998	Stoven, V., et al.	
	WO-02/087306A2	11/07/2002	Callamaras, N. , et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ARCAMONE, F M., "From the Pigments of the Actinomycetes to Third Generation Antitumor Anthracyclines", <u>Biochimie (Paris)</u> , 80(3), (March 1998), 201-206	
		ELLIOTT, P J., et al., "Recent Advances in Understanding Proteasome Function", <u>Current Opinion in Drug Discovery and Development</u> , 5 (2), ISSN: 1367-6733,(1999),484-490	
		KIYOMIYA, K.-I., et al., "The Role of the Proteasome in Apoptosis Induced by Anthracycline Anticancer Agents", <u>International Journal of Oncology</u> , 20 (6), (June 2002),1205-1209	
		MENG, L., et al., "Epoxomicin, a Potent and Selective Proteasome Inhibitor, Exhibits <i>in vivo</i> Antiinflammatory Activity", <u>Proceedings of the National Academy of Sciences of USA</u> , 96 (18), (August 31, 1999), 10403-10408	
		SPINDLER, B. , et al., "Characterization of Early Aldosterone-induced RNAs identified in A6 Kidney Epithelia", <u>Pfluegers Archiv</u> , Vol. 434, Springer Verlag, Berlin, DE, (1997), 323-331	
		YAN, Z., et al., "Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway Epithelia", <u>Journal of Virology</u> , 78, (Mar., 2004),2863-2874	
		ZENTNER, M. D., "The Amiloride-Sensitive Epithelial Sodium Channel α -Subunit is Transcriptionally Down-Regulated in Rat Parotid Cells by the Extracellular Signal-Regulated Protein Kinase Pathway", <u>The Journal of Biological Chemistry</u> , 273(46), (1998),30770-30776	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached